To address these clinically relevant questions, we evaluated the expression landscape of HER2 in metastatic prostate cancer and urothelial carcinoma using a validated HER2 IHC assay and determined genomic features underlying differential expression. The gene discussed is ERBB2; the disease is metastatic prostate carcinoma.